D Bradley Welling Selected Research

Acoustic Neuroma (Acoustic Neurinoma)

10/2021	Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.
1/2020	MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas.
11/2018	Publisher Correction: Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma.
1/2018	Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma.
5/2017	Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
11/2016	Sulforaphane, a natural component of broccoli, inhibits vestibular schwannoma growth in vitro and in vivo.
1/2016	Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
2/2012	Treatment of vestibular schwannoma cells with ErbB inhibitors.
1/2012	Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.
9/2011	AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D Bradley Welling Research Topics

Disease

22	Neoplasms (Cancer) 10/2021 - 09/2002
18	Acoustic Neuroma (Acoustic Neurinoma) 10/2021 - 09/2002
11	Neurilemmoma (Schwannoma) 01/2021 - 09/2002
10	Meningioma (Meningiomas) 10/2021 - 09/2011
5	Neurofibromatosis 2 (Neurofibromatosis Type II) 10/2021 - 01/2002
4	Hearing Loss (Hearing Impairment) 07/2021 - 10/2016
4	COVID-19 05/2021 - 01/2020
4	Carcinogenesis 01/2020 - 09/2002
3	Neurofibromatoses (Neurofibromatosis) 10/2021 - 01/2018
2	Infections 10/2020 - 02/2014
2	Sneezing 07/2020 - 01/2020
2	Neurofibrosarcoma (MPNST) 01/2016 - 06/2009
2	Wounds and Injuries (Trauma) 02/2014 - 05/2012
2	Otosclerosis 06/2008 - 09/2003
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 06/2022
1	Otitis Media 05/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Plexiform Neurofibroma 01/2021
1	Tympanic Membrane Perforation 08/2020
1	High-Frequency Hearing Loss 01/2020
1	Brain Abscess (Abscess, Brain) 06/2018
1	Cicatrix (Scar) 02/2014
1	Tinnitus 07/2011
1	Inflammation (Inflammations) 06/2008
1	Ependymoma 02/2008
1	Cerebrospinal Fluid Rhinorrhea 10/2007
1	Carcinoma (Carcinomatosis) 03/2006

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 01/2018 - 09/2002
5	Histone Deacetylase InhibitorsIBA 10/2021 - 09/2011
5	Pharmaceutical PreparationsIBA 10/2021 - 09/2011
4	AerosolsIBA 05/2021 - 01/2020
4	Neurofibromin 2 (Merlin)IBA 01/2018 - 02/2006
3	Complementary DNA (cDNA)IBA 09/2002 - 01/2002
3	RNA (Ribonucleic Acid)IBA 09/2002 - 01/2002
2	Phosphotransferases (Kinase)IBA 01/2021 - 02/2012
2	Mifepristone (RU 486)FDA Link 11/2018 - 01/2018
2	Anti-Bacterial Agents (Antibiotics)IBA 06/2018 - 02/2014
2	Eukaryotic Initiation Factor-4F (EIF4F)IBA 01/2018 - 01/2016
2	silvestrolIBA 01/2018 - 01/2016
2	Eukaryotic Initiation Factor-4EIBA 01/2018 - 01/2016
2	LuciferasesIBA 02/2015 - 01/2002
2	Antineoplastic Agents (Antineoplastics)IBA 10/2013 - 05/2009
2	CyclinsIBA 03/2006 - 09/2002
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	AZD 6244IBA 01/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021
1	AntioxidantsIBA 01/2021
1	brigatinibIBA 01/2021
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 08/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Peptide Hydrolases (Proteases)FDA Link 01/2020
1	Peptide Initiation Factors (Initiation Factor)IBA 01/2018
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2018
1	Progesterone FDA LinkGeneric 01/2018
1	Drug CombinationsIBA 01/2018
1	Carrier Proteins (Binding Protein)IBA 01/2018
1	PanobinostatIBA 01/2018
1	Small Interfering RNA (siRNA)IBA 01/2018
1	omipalisibIBA 01/2018
1	Eukaryotic Initiation Factor-4G (Eukaryotic Initiation Factor 4G)IBA 01/2018
1	ponatinibIBA 05/2017
1	sulforaphaneIBA 11/2016
1	Histones (Histone)IBA 01/2016
1	PhytochemicalsIBA 01/2016
1	FRAX597IBA 02/2015
1	p21-Activated KinasesIBA 02/2015
1	cucurbitacin DIBA 10/2013
1	furanoheliangolideIBA 10/2013
1	NucleotidesIBA 01/2013
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2013
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2012
1	tyrosine receptor (receptor, tyrosine)IBA 02/2012
1	ErbB Receptors (EGF Receptor)IBA 02/2012
1	Lapatinib (GW572016)FDA Link 02/2012
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2012
1	Biological ProductsIBA 01/2012
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2012
1	MelatoninIBA 07/2011
1	OSU 03012IBA 06/2009
1	Celecoxib (Celebrex)FDA Link 06/2009
1	Phosphatidylinositols (Phosphatidylinositol)IBA 06/2009
1	Tumor Viral Antigens (Large T Antigen)IBA 06/2009
1	InterleukinsIBA 06/2008
1	ProplastIBA 10/2007
1	AntibodiesIBA 03/2006
1	Cyclin DIBA 03/2006

Therapy/Procedure

9	Therapeutics 01/2021 - 02/2006
4	Craniotomy 06/2022 - 10/2007
3	Drug Therapy (Chemotherapy) 01/2021 - 01/2018
3	Cochlear Implants (Cochlear Implant) 01/2020 - 06/2007
2	Mastoidectomy 01/2021 - 10/2020
1	Treatment Delay 07/2021
1	Ambulatory Care (Outpatient Care) 10/2020
1	Nebulizers and Vaporizers (Inhaler) 07/2020
1	Aftercare (After-Treatment) 01/2018
1	Debridement 02/2014
1	Rhytidoplasty (Facelift) 02/2014
1	Hyperbaric Oxygenation 02/2014
1	Lasers (Laser) 05/2012
1	Cochlear Implantation 06/2007